ofininvitroA preliminary research suggests that early use of drug rasagiline may prove helpful to slow down the progression of Parkinson’s disease.

The researchers found that the patients who took that drug soon after diagnosis, they suffered a less aggressive form of Parkinson’s than the patients who didn’t take rasagiline until later.

The study, which involved more than 1,000 patients, has been presented at a neurological conference in Madrid.

There are more than 120,000 patients with Parkinson’s in UK and each year more than 10,000 new cases are diagnosed. Shakes, stiffening of the muscles and memory loss are some common symptoms of the disease. Rasagiline or Azilect has been approved by the NHS to ease these symptoms.

On the other hand, some doctors are unwilling to prescribe that drug at early stage and they concern that the effect can decrease with time.

In this latest study, patients from the UK, US and Europe were involved and it found that patients, who took rasagiline soon after diagnosis, had a better condition after 18 months than the patients who had a nine months delayed treatment with the drug.

According to researchers the drug works by creating a longer protection for brain cells. However, they also stressed that most of the patients had been taking part in the trial for 18 months and the researchers needed more work to find its long-term impact.

Professor David Burn, who led the study, described the results as ‘exciting’.
“The results show that the early use of rasagiline can help to slow down the progression of the disease,” he says.

Related links

This article is the property ofhttp://www.healthhype.com
Copying and publishing any article from our site is strictly NOT allowed